Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension of spesolimab in adults with hidradenitis suppurativa
2020-005587-55Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started Mar 2021; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-005587-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005587-55.